Shots:
- Ionis has granted Recordati exclusive rights to develop & commercialize zilganersen for Alexander disease outside the US, while Ionis retains US commercialization rights & will continue to lead global development
- Ionis will receive $30M upfront & additional milestone payments, with tiered royalties of up to the mid-20% range on annual net sales. Recordati will oversee regulatory filings, commercialization, & country-specific early access pathways outside the US
- Additionally, Ionis plans to independently commercialize zilganersen in the US, where the therapy is under FDA review with a PDUFA action date of Sep 22, 2026
Ref: Businesswire | Image: Ionis & Recordati | Press Release
Related News: Ionis’ Zilganersen Receives US FDA Priority Review for Alexander Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
